N/A N=10 Circadian Brown Adipose Tissue Metabolism
Healthy
Primary: Change in Maximum Standardized Update Value (SUVmax) in Brown Adipose Tissue FDG Uptake in the Neck or Upper Chest on Evening and Imaging Compared to Morning Imaging
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=11 Investigating Brown Adipose Tissue Activation in Humans
Metabolic Diseases
Primary: Brown Adipose Tissue Activation Following Glucagon or Saline Infusion — 0.074; 0.010; 0.029 MR[gluc] umol/kg/min — p=<0.01
Phase 2 N=12 Effects of b3-Adrenergic Receptor Agonists on Brown Adipose Tissue
Obesity
Primary: BAT Activity as Measured by 18F-FDG PET/CT — 0.92; 132 mL*SUVmean*g/mL — p=0.001
N/A N=32 Brown Adipose Tissue as a Therapeutic for the Metabolic and Cardiac Dysfunction With Senescence (BATSR)
Metabolic Diseases
Primary: Collection of Imaging of BAT by Magnetic Resonance Imaging — 78.69; 82.58; 82.45 Percentage
N/A N=69 Brown Adipose Tissue Activity in Pre- and Postmenopausal Women
Menopause · Obesity
Primary: Brown Adipose Tissue Volume — 53.1; 20.6 mL
N/A N=28 Does Cold Provocation Increase Brown Adipose Tissue Volume?
Brown Adipose Tissue, Human
Primary: Brown Adipose Tissue, Absolute Volume — 0.0066; 0.0021 liters
N/A N=5 Sympathetic Activation in Obesity
Obesity · Healthy
Primary: Distribution Volume Ratio (DVR) of [11C]MRB PET Imaging of Peripheral Sympathetic Nervous System — 0.13; -0.025; 0.095; -0.03 DVR
N/A N=93 Exercise Regulation of Human Adipose Tissue
Healthy · Obese · Diabetes Mellitus, Type 2
Primary: Changes in Human Adipose Tissue Characteristics Following Exercise Training — 25.45; 34.12; 38.06; 27.05 body fat %
N/A N=137 Beige Fat, Energy, and the Natriuretic Peptide System
Obesity
Primary: Adipose Tissue Gene Expression of UCP1 (Uncoupling Protein 1)- Differences by Obesity Status — 7.79; 24.33 fold change — p=<0.01
Phase 2 N=47 Study of Human Non-Shivering Thermogenesis and Basal Metabolic Rate
Healthy Volunteers
Primary: Resting Energy Expenditure at Low Temperature — 1.277; 1.134; 1.300; 1.271 kcal/min
N/A N=10 Measurement of Body Fat in Infants
Brown Adipose Tissue · Body Composition
Primary: Whole Body Fat Mass — 20.8 percentage of fat mass
Phase 2 N=17 MIrabegron and Physiological Function in Cold Environments
Resting Energy Expenditure · Thermogenesis · Brown Adipose Tissue
Primary: Cold Temperature Deflection Point — 22.8; 22.97 degrees Celsius
Phase 2 N=30 Mirabegron and Physiological Function in Cold Environments
Resting Energy Expenditure · Thermogenesis · Brown Adipose Tissue
Primary: Cumulative Resting Energy Expenditure — 456.4; 494.7; 481.3; 492.8 kcal
Phase 3 N=31 Thyroid Hormones Homeostasis and Energy Metabolism Changes During Stimulation of Endogenously Secreted Bile Acids (BAs)
Healthy Volunteers
Primary: Energy Expenditure — 1.37; 1.40; 1.28; 1.27 kcal/min — p=0.0001
Phase 4 N=23 GLP-1 Therapy: The Role of IL-6 Signaling and Adipose Tissue Remodeling in Metabolic Response
Glucose Intolerance · Overweight and Obesity · Drug Effect
Primary: Cytokine Interleukin-6 (IL-6) Messenger Ribonucleic Acid (mRNA) Level (From Adipose Tissue) — 7.88; 7.67 natural log(arbitrary units)
N/A N=26 Fatty Acid Oxidation Disorders & Body Weight Regulation Grant
Trifunctional Protein Deficiency
Primary: An Outcome of This Study is the Difference in Percent Body Fat (%BF) Between Subjects With a Long-chain Fatty Acid Oxidation Disorder and Normal Controls. — 31.8; 27.2…
N/A N=20 Changes in Ectopic Fat Following Surgically Induced Weight Loss
Obesity · Type 2 Diabetes
Primary: Pancreatic and Liver Triglyceride (Fat) Content — 6.44; 2.08 percent
N/A N=124 Newborn Feeding and Infant Phenotype
Breast Feeding
Primary: Change in Total Adipose Tissue Volume — 0.718; 0.901; 0.775 Litres
N/A N=63 Cellular Dynamics of Subcutaneous Fat Distribution in Obese Women
Obesity · Metabolic Syndrome
Primary: In Vivo Adipose Cell Formation (Adipogenesis) — -0.3; 1.8; -1.2; 2.1 percent
N/A N=60 Non-invasive Cooling of Subcutaneous Fat
Fat Disorder
Primary: Change in Fat Layer Thickness of the Treated Flank — -18.7; -22.6; -17.8; -17.5 percent fat layer change
N/A N=29 Clinical Effectiveness of Body Fat Distribution Imaging in Real-World Practice: The BODY-REAL Study
Overweight and Obesity · PreDiabetes · Type 2 Diabetes
Primary: Change in BMI — 0.43; 0; 4.4; 0 kg/m2 — p=0.2
Phase 4 N=38 Liraglutide Effects on Epicardial Fat Inflammatory Genes
Type2 Diabetes · Coronary Artery Disease
Primary: EAT Inflammation — 0.70; 1.4; 0.39; 0.25 ct (cycle threshold)
N/A N=17 Chronic Passive Heating in Individuals With T2DM
Type2 Diabetes
Primary: Insulin Sensitivity — 0.31; 0.33; 0.10; 0.10 AU
N/A N=175 Non-Invasive Cooling of Fat Cells
Reduction of Unwanted Fat
Primary: Percentage of Participants With Visible Improvement in Treated Area — 65.2; 82.8 percentage of participants
N/A N=20 Study of Lipolysis of Visceral Reserve Fat Using Tecar Therapy.
Obesity, Visceral · Obesity; Endocrine
Primary: Visceral Fat Loss (cm3) — -628 cm3
N/A N=95 Investigation of the Effects of a Bifidobacterium Breve Strain on Fat Loss in Healthy Adults
Obesity · Overweight and Obesity
Primary: Change in Fat Loss (g) — -78.38; -9.43 g
N/A N=101 Role of Pancreatic Triglyceride Content in Beta-cell Function
Obesity · Type 2 Diabetes
Primary: Pancreatic and Liver Fat — 1.87; 6.57; 3.61; 5.85 percent
N/A N=33 Training Effects on Skeletal Muscle Fatty Acid Metabolism
Healthy Volunteers
Primary: Insulin Sensitivity as Measured by Hyperinsulinemic Euglycemic Clamp at a Single Time Point (6 Hrs) After Intralipid or Glycerol Infusion — 8; 12; 6; 11 M value — p=<0.05
Phase 1 N=22 PED NEONAT 20-000599 Fetal Body Composition
IUGR · Gestational Diabetes · Pregnancy Related
Primary: Maternal Visceral Adipose Tissue Volume — 97593; 169626; 96787 mm3
Phase 4 N=88 Optimizing Body Composition for Function in Older Adults
Obesity · Overweight With Indications for Weight Loss
Primary: Appendicular Non-bone Lean Mass — -2.53; -2.49; -2.04; -1.45 kg